A Study of Intrapleural Administration of Bevacizumab and Camrelizumab for Malignant Pleural Effusion
Status:
Not yet recruiting
Trial end date:
2024-08-31
Target enrollment:
Participant gender:
Summary
Patients with a variety of malignancies can develop malignant pleural effusion (MPE). MPE can
cause significant symptoms and result in a marked decrease in quality of life and a poor
prognosis. MPE is primarily considered as an immune and vascular manifestation of pleural
metastases. The combined use of anti-angiogenic therapy and immunotherapy may be a promising
strategy for MPE.
This is a Phase Ib/II clinical trial to evaluate the safety and tolerability of administering
bevacizumab and camrelizumab into the intrapleural space of subjects with malignant pleural
effusion through a pleurX catheter.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital of Zhengzhou University